Natural Capsules Limited
All news and filings related to Natural Capsules Limited.
View all news & filings- Medium impact
Natural Capsules Limited: EGM Approves Preferential Allotment of Equity Shares and Warrants
Natural Capsules Limited's EGM on September 09, 2026, approved two special resolutions for preferential allotments. Shareholders overwhelmingly supported the issuance of equity shares and convertible warrants, with over 99.99% of votes in favor for both. The meeting was held via VC/OAVM.
Read the summary - Medium impact
Natural Capsules Limited Holds 1st EGM 2026 for Preferential Allotment
Natural Capsules Limited held its 1st EGM on September 9, 2026, to approve a preferential allotment of equity shares and warrants. The meeting included remarks on the preferential issue and voting by members. Results of the voting will be submitted separately.
Read the summary - Medium impact
Natural Capsules Limited Announces EGM on Sep 9 to approve Preferential Issue
Natural Capsules Limited will hold an EGM on September 9, 2026, to approve a preferential issue. This includes up to 1,12,500 equity shares at ₹178 each and 450,000 warrants at ₹178 each. The revisions follow queries from stock exchanges and are based on a recent valuation report.
Read the summary - Medium impact
Natural Capsules Dispatch Corrigendum for EGM, Revises Preferential Issue Terms
Natural Capsules dispatched a corrigendum for its EGM notice, revising preferential issue terms. It will issue up to 1,12,500 equity shares at ₹178 each and 4,50,000 warrants at ₹178 each. Funds will be used for working capital and capital expansion. EGM scheduled for September 09, 2026.
Read the summary - Medium impact
Natural Capsules Approves Preferential Issue of Shares and Warrants, Boosts Promoter Holding
Natural Capsules approved a preferential issue of 1,12,500 equity shares and 4,50,000 warrants at ₹178 each. The issue aims to increase promoter holding to 10.61%. An EGM is scheduled for September 9, 2026. The preferential issue aggregates ₹2,00,25,000 for shares and ₹8,01,00,000 for warrants.
Read the summary - Low impact
Natural Capsules Limited Announces EGM on September 9, 2026
Natural Capsules Limited will hold an Extraordinary General Meeting (EGM) on September 9, 2026, at 12:00 PM IST. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM). Members are advised to update their email addresses for communication.
Read the summary - Low impact
Natural Capsules Ltd. Sets Record Date for EGM on Sep 2, 2026
Natural Capsules Limited has announced September 2nd, 2026, as the record date for its Extraordinary General Meeting (EGM). The EGM is scheduled to take place on September 9th, 2026.
Read the summary - Medium impact
Natural Capsules Announces EGM on Sep 9, 2026 for Preferential Share/Warrant Issue
Natural Capsules Limited will hold an EGM on September 9, 2026, to approve a preferential issue of 1,25,000 equity shares worth ₹2.00 Crores and 5,00,000 warrants worth ₹8.00 Crores to promoter Sunil Laxminarayan Mundra. Remote e-voting is open from September 4-8, 2026.
Read the summary - Low impact
Natural Capsules Ltd: Independent Director Resigns from Material Unlisted Subsidiary
Mr. Pramod Kasat has resigned as an Independent Director from Natural Biogenex Private Limited, a material unlisted subsidiary of Natural Capsules Limited. The resignation is effective August 17, 2026, due to professional commitments.
Read the summary - Low impact
Natural Capsules Ltd. Announces Q1 FY27 Unaudited Financial Results
Natural Capsules Limited reported its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results on August 12, 2026. The announcement was published in newspapers on August 14, 2026, and is available on the company and stock exchange websites.
Read the summary - Medium impact
Natural Capsules Ltd. AGM Voting Results: All Resolutions Passed Unanimously
Natural Capsules Limited's 33rd AGM on August 12, 2026, resulted in all six resolutions being passed with overwhelming majority. Key approvals included the FY26 financial statements, re-appointment of directors Mrs. Jyoti Mundra and Mr. Laxminarayan Moondra, and revised remuneration for Mr. Laxminarayana Moondra and Mr. Shrey Mundra.
Read the summary - Medium impact
Natural Capsules Q1FY27 Results: Revenue at ₹48.71 Cr, PAT at ₹(5.74) Cr
Natural Capsules Limited reported Q1FY27 consolidated results with revenue at ₹48.71 crore (down 17% Q-o-Q, up 8% Y-o-Y). PAT was a loss of ₹5.74 crore (up 15% Q-o-Q). EBITDA margin improved to 2.30% (up 159 BPS Y-o-Y). Management cited ERP disruption and inventory deferral impacts. HPMC segment faced US market challenges, leading to line conversions.
Read the summary - Low impact
Natural Capsules Subsidiary Appoints K. H. Honneshaiah as COO
Natural Capsules Limited's subsidiary, Natural Biogenex Private Limited, has appointed Mr. K. H. Honneshaiah as its new Chief Operating Officer. Mr. Honneshaiah possesses 36 years of experience in operations and manufacturing leadership within the pharmaceutical sector.
Read the summary - Medium impact
Natural Capsules Board Approves Financial Results & Preferential Issue of Warrants
Natural Capsules approved Q1 FY27 results and a preferential issue of equity shares and warrants worth ₹2 crore and ₹8 crore respectively, at ₹160 per share to the promoter group. An EGM is scheduled for September 9, 2026.
Read the summary - Medium impact
Natural Capsules Approves Preferential Issue of Warrants and Financial Results
Natural Capsules approved Q1 FY27 results and a preferential issue of ₹10 crore (₹2 crore equity shares, ₹8 crore warrants) to promoters at ₹160/share. An EGM is scheduled for September 9, 2026, to approve these issuances.
Read the summary - Low impact
Natural Capsules Ltd Holds 33rd AGM on August 12, 2026; Financials and Director Appointments Discussed
Natural Capsules Limited held its 33rd AGM on August 12, 2026. Key discussions included adopting FY26 financial statements, re-appointing directors Mrs. Jyoti Mundra and Mr. Laxminarayan Moondra, and approving revised remuneration for Mr. Laxminarayana Moondra and Mr. Shrey Mundra. Related party transactions were also approved.
Read the summary - Low impact
Natural Capsules Subsidiary Allots 9.46 Lakh Rights Shares Worth ₹94.6 Lakh
Natural Biogenex Private Limited, a subsidiary of Natural Capsules Limited, has approved the allotment of 9,46,305 equity shares. This allotment, part of a Rights Issue approved on July 10, 2026, is valued at ₹94.63 Lakh.
Read the summary - Medium impact
Natural Capsules Limited to See 2.18% Stake Dilution in Subsidiary
Natural Capsules Limited will experience a 2.18% dilution in its stake in subsidiary Natural Biogenex Private Limited due to non-participation in its rights issue. The subsidiary reported a turnover of ₹13.43 crore and a net worth of ₹81.24 crore last fiscal year.
Read the summary - Low impact
Natural Capsules Ltd. Announces 33rd AGM on Aug 12, 2026; E-voting from Aug 8
Natural Capsules Limited will hold its 33rd Annual General Meeting on August 12, 2026, via video conference. The company has completed dispatching the AGM notice and Annual Report for FY 2025-26. Remote e-voting for members will be open from August 8 to August 11, 2026, with a cut-off date of August 5, 2026.
Read the summary - Medium impact
Natural Capsules Limited Announces 33rd AGM on August 12, 2026
Natural Capsules Limited will hold its 33rd AGM on August 12, 2026, via VC/OAVM. Key agenda items include adopting FY26 financial statements, director re-appointments, and approving related party transactions up to ₹50 crore with a subsidiary. Mr. Laxminarayana Moondra's re-appointment as Whole-time Director and revised remuneration for Mr. Shrey Mundra are also on the agenda. The record date is August 05, 2026.
Read the summary - Low impact
Natural Capsules Limited Sets Record Date for 33rd AGM on August 5, 2026
Natural Capsules Limited has announced August 5, 2026, as the record date for its 33rd Annual General Meeting. The AGM itself is scheduled for August 12, 2026.
Read the summary - Low impact
Natural Capsules Ltd. announces 33rd AGM on August 12, 2026, via VC/OAVM
Natural Capsules Limited will hold its 33rd Annual General Meeting on August 12, 2026, at 12:00 PM. The meeting will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The Annual Report 2025-26 and AGM notice will be sent via email.
Read the summary - Low impact
Natural Capsules Ltd Submits SEBI Reg 74(5) Certificate for Q1 FY27
Natural Capsules Limited submitted its SEBI Regulation 74(5) certificate for the quarter ended June 30, 2026. The RTA confirmed processing of dematerialized securities and adherence to listing and registration requirements.
Read the summary - Medium impact
Natural Biogenex Approves Rights Issue of ₹1.12 Crore
Natural Biogenex Private Limited, an unlisted subsidiary of Natural Capsules Limited, approved a Rights Issue on July 10, 2026. The issue comprises 11,16,766 equity shares at Rs. 10 each, totaling ₹1.12 crore.
Read the summary - Low impact
Natural Capsules Subsidiary Allots 1.11 Lakh Equity Shares Worth ₹11.12 Lakh via Rights Issue
Natural Capsules' subsidiary, Natural Biogenex Private Limited, approved the allotment of 1,11,202 equity shares worth ₹11.12 Lakh on July 10, 2026. This follows a Right Issue approved on May 27, 2026.
Read the summary - Low impact
Natural Capsules Ltd. Notifies Newspaper Publication for Share Transfer to IEPF
Natural Capsules Limited published a notice in Business Line and Sanjevani newspapers regarding the mandatory transfer of shares to the Investor Education and Protection Fund (IEPF). Unclaimed dividends from FY 2018-19 and corresponding shares will be transferred to IEPF on or after July 25, 2026.
Read the summary - Medium impact
Natural Capsules Q4 FY26 Earnings Call Transcript Released
Natural Capsules reported Q4 FY26 revenue of ₹58.45 crores, up 30% YoY. Full-year FY26 revenue grew 11% to ₹187.20 crores, but the company posted an EBITDA loss of ₹1.56 crores and a net loss of ₹24.66 crores due to plant disruptions and API subsidiary costs. For FY27, consolidated revenue is projected at ₹274 crores, with ₹20 crores from new HPMC capsules.
Read the summary - Low impact
Natural Capsules Ltd. Releases Audio Recording of Conference Call Held on June 2, 2026
Natural Capsules Limited has released the audio recording of its conference call held on June 2, 2026. The recording is available on the company's website as per SEBI regulations.
Read the summary - Low impact
Natural Capsules Ltd: Corrigendum on Rights Issue Details for Subsidiary
Natural Capsules Limited corrected its subsidiary's rights issue details. The number of shares is now 11,11,205, with total proceeds of ₹1.11 crore. This is a correction to a prior filing.
Read the summary - Low impact
Natural Capsules Schedules Investor Conference Call for Q4 & FY26 Results on June 2, 2026
Natural Capsules Limited will host an investor conference call on June 2, 2026, at 4:00 PM IST to discuss audited financial results for Q4 and FY26 ended March 31, 2026. Management, including MD Sunil Mundra and CFO Raj Kishore Prasad, will participate.
Read the summary - Low impact
Natural Capsules Limited Announces Audited Financial Results for Q4FY26
Natural Capsules Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results on May 27, 2026. The details were published in Business Line and Sanjevani on May 29, 2026.
Read the summary - Medium impact
Natural Capsules Q4FY26: Revenue Jumps 55% QoQ to ₹58.45 Cr, PAT at ₹4.98 Cr
Natural Capsules Limited reported Q4FY26 consolidated revenue of ₹58.45 Cr, up 55% QoQ. PAT was ₹4.98 Cr, up 30% QoQ but down 1,056% YoY. Standalone capsules business contributed ₹36 Cr. Subsidiary signed a manufacturing agreement with Fermbox Bio. Commercial API sales commenced in Q4FY26.
Read the summary - Medium impact
Natural Capsules Q4 & FY26 Results: Revenue Up 1.33 Cr, PAT at ₹4.98 Cr
Natural Capsules Limited reported Q4 FY26 revenue of ₹58.45 crore and PAT of ₹4.98 crore. For FY26, revenue was ₹187.20 crore with PAT at ₹(24.66) crore. The company expects revenue from a new HPMC line from H2 FY27. A collaboration with Fermbox Bio for fermentation technology was also announced.
Read the summary - Low impact
Natural Capsules to Host Investor Conference Call on June 2, 2026, for Q4 & FY26 Results
Natural Capsules Limited will hold an investor conference call on June 2, 2026, at 4:00 PM IST. The call will focus on discussing the audited financial results for the fourth quarter and the year ended March 31, 2026, along with the business outlook. Management will be present.
Read the summary - Medium impact
Natural Capsules Appoints New Company Secretary, Approves FY26 Financials
Natural Capsules Limited approved audited standalone and consolidated financial results for FY26 ended March 31, 2026. Mr. Akshay Dutta appointed Company Secretary & Compliance Officer. Mr. Shri Laxminarayana Moondra re-appointed Whole-time Director for 3 years. 25,000 ESOPs allotted, increasing paid-up capital to ₹10.41 crore.
Read the summary - Medium impact
Natural Biogenex Approves Rights Issue of ₹1.11 Crore
Natural Biogenex Private Limited, a material subsidiary of Natural Capsules Limited, approved a rights issue. The issue comprises 11,11,200 equity shares of ₹10 each, totaling ₹1.11 crore. The approval was granted at a Board meeting on May 27, 2026.
Read the summary - Medium impact
Natural Capsules Board Approves FY26 Results, Reappoints Director, Appoints New CS
Natural Capsules Limited's Board approved FY26 audited standalone and consolidated results. Mr. Shri Laxminarayana Moondra was re-appointed as Whole-time Director for 3 years. M/s. Mallya & Mallya appointed Internal Auditors for FY27. Mr. Akshay Dutta is the new Company Secretary & Compliance Officer. 25,000 ESOP shares were allotted.
Read the summary - Medium impact
Natural Capsules Board Approves FY26 Results, Reappoints Director, Hires CS
Natural Capsules Limited approved audited standalone and consolidated financial results for FY26. Mr. Shri Laxminarayana Moondra was re-appointed as Whole-time Director for 3 years, effective July 28, 2026. M/s. Mallya & Mallya appointed Internal Auditors for FY27. Mr. Akshay Dutta appointed Company Secretary & Compliance Officer. 25,000 ESOP shares allotted.
Read the summary - Medium impact
Natural Capsules Board Approves FY26 Results, Re-appoints Director, Appoints CS & Internal Auditor
Natural Capsules Limited's Board approved FY26 results. Mr. Shri Laxminarayana Moondra was re-appointed Whole-time Director for 3 years. M/s. Mallya & Mallya appointed Internal Auditors, and Mr. Akshay Dutta named Company Secretary. 25,000 equity shares were allotted under ESOP, increasing share capital to ₹10,41,11,540.
Read the summary - Low impact
Natural Capsules Ltd: Company Secretary & Compliance Officer Resigns
Ms. Pranjal Deshmukh has resigned as Company Secretary and Compliance Officer of Natural Capsules Limited. Her resignation is effective April 25, 2026. She is leaving to pursue better career opportunities.
Read the summary - Low impact
Natural Capsules Limited Announces Investor Education Campaign
Natural Capsules Limited is participating in the "Saksham Niveshak" campaign by the Investor Education and Protection Fund Authority. This initiative encourages shareholders with unpaid dividends to claim them and update KYC details. The campaign aims to connect with shareholders before dividends are transferred to the IEPF.
Read the summary - Low impact
Natural Capsules Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends
Natural Capsules Limited is participating in the 'Saksham Niveshak' campaign from April 1 to July 9, 2026. This initiative encourages shareholders to claim unpaid dividends and update KYC details. Shareholders can contact the RTA or the company for assistance.
Read the summary - Low impact
Natural Capsules Ltd Files Certificate Under SEBI Regulations for Q4 FY26
Natural Capsules Limited filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending March 31, 2026. The RTA confirmed securities are listed and dematerialized certificates were processed as per regulations.
Read the summary - Low impact
Natural Capsules Ltd. Publishes Newspaper Notice for Share Transfer & Dematerialization Window
Natural Capsules Limited has published newspaper notices regarding a special window for the transfer and dematerialization of physical shares. This window is open from February 5, 2026, to February 4, 2027. It allows shareholders to lodge transfer deeds executed before April 1, 2019, that were previously rejected.
Read the summary - Medium impact
Natural Capsules Ltd. Shareholders Approve Investment Limits Enhancement via Postal Ballot
Natural Capsules Limited shareholders approved a special resolution to enhance investment, loan, guarantee, and security limits under Section 186 of the Companies Act, 2013. The resolution passed with 99.9962% in favour via postal ballot e-voting, which concluded on March 27, 2026.
Read the summary - Low impact
Natural Capsules Limited Closes Trading Window from April 1, 2026, for FY26 Financial Results
Natural Capsules Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. The date for the Board Meeting to approve these results will be announced later.
Read the summary - Low impact
Natural Capsules Limited Credit Rating Reaffirmed at BB+(Stable)/A1+
Natural Capsules Limited's long-term facilities received a credit rating of BB+(Stable) and short-term facilities were rated A1+ by Infomerics Valuation and Rating Limited. The total rated facilities amount to ₹59.15 crore.
Read the summary - Medium impact
Natural Biogenex Partners Fermbox Bio for Fermentation CDMO Services with ₹60 Crore Investment
Natural Biogenex, a subsidiary of Natural Capsules Limited, has partnered with Fermbox Bio Private Limited. The agreement includes up to ₹60 crore for fermentation technology and equipment placement. This collaboration aims to enhance fermentation-based CDMO services for global biotech and biopharma clients.
Read the summary - Medium impact
Natural Capsules Subsidiary Signs Manufacturing Pact with Fermbox Bio, Involves ₹60 Crore Investment
Natural Capsules' material subsidiary, NBPL, has signed manufacturing agreements with Fermbox Bio. Fermbox Bio will use NBPL's fermentation plant capacity and invest up to ₹60 Crore in machinery. This is a strategic partnership for contract manufacturing.
Read the summary - Low impact
Natural Capsules Limited Publishes Newspaper Advertisement for Postal Ballot Notice
Natural Capsules Limited published newspaper ads for its Postal Ballot Notice. Members are voting on enhancing limits for investments, loans, guarantees, and securities under Section 186 of the Companies Act, 2013. E-voting is open from February 26 to March 27, 2026. Results expected by March 31, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio